Member Info for MikeF

1 mill buy just in @ .058p. Sudden interest... maybe news is due?

Buy on PLUS, 904,998 @ .0585p.

I'm a happy bunny, just grabbed some more at 3.9p :) GLA

Very much doubt that. How did you do on WEST?

.7507p to buy .75p to sell. GLA

Looks like you read this one wrong...

.76p to buy (under mid) GLA

What are you getting on a dummy? I was getting .058p, way under mid last week. Not tried yet this morning.

How exactly is this a multibagger?

Hi mate, yes a huge discount to the recent placing price, one of the reasons i initially got in... since my initial buy i have been doing some extensive research and if you look through my previous posts you will see a few collaborations & T/O's between pharmas and small biomarker companies. I think it's only a matter of time before we get snapped up with our technology. All IMHO of course & DYOR. GLA

I decided to write to CFO after Fridays fall , reply below good evening Whilst the company cannot be entirely held responsible for its share price, it is a reflection of how the market values us rather than necessarily how the business is performing, you are correct to point out that sales of Optim and Midas have not yet shown the ramp up that we would have liked. The two have separate issues. Midas is delayed on its launch through a technical issue which has now been resolved. We are looking to put it into some “live test situations” during August with a view to launch shortly after that, subject to performance in the live situations. Optim is slower to ramp up than we would like. Technical take up is very good indeed, meaning that the technicians and scientists value the work that it does for them. Order intake, however, has been disappointing and we believe that an element of this remains capex freeze or deferrals in the market. We are working extremely hard to accelerate as much as we possibly can. We are in the process of appointing distributors to give us a wider reach than our direct sales force possibly could. Our pipeline is looking stronger and we can see progress in the quality of the leas that we are taking on. I understand your frustration and we share that. You may have seen that those elements of the Board that could invest did invest in the recent fund raise. We believe there is value in Avacta and I hope that you can persevere Regards Tim Sykes CFO, Avacta Group plc

http://www.aimzine.co.uk/aimzine/0810/0810_B2/0810_B2.htm

whether some of this overdone fall gets corrected today, hopefully all or most of the RHPS holders are already out that want out! GLA

in the Biomarker industry, will it be out turn next? NEW YORK (GenomeWeb News) – Cancer molecular diagnostics developer Pathwork Diagnostics announced today a collaboration with Novartis for the discovery of cancer biomarkers. The biomarkers will be used as a basis for diagnostics "across a range of cancer types," the Redwood City, Calif.-based firm said in a statement. Under the terms of the deal, both companies have the rights to develop and commercialize the diagnostic products. Further terms were not disclosed. Last month Pathwork Diagnostics received clearance from the US Food and Drug Administration for use of its microarray-based Tissue of Origin test with formalin-fixed embedded tissue. http://www.genomeweb.com//node/946389?hq_e=el&hq_m=776849&hq_l=2&hq_v=7d12dee5b6

Exactly, hence i was very grateful for the SELL rating lol Got a nice chunk at a very good price.

Thanks for posting that, RHPS had a similar effect on LPX when they announced a sell on them! The next day i think it was the directors were buying as they could get cheap shares and were obviously very grateful to Tom lol. The products here are great and once sales pick up this should move significantly northward. Another revenue earner for the company is about to hit the market, MIDAS. This should also bring a material uplift to sales revenue. GLA

Avacta raises more than £1m from share placing: http://www.yorkshirepost.co.uk/businessnews/Avacta-raises-more-than-1m.6402251.jp

Tom Bulford and his sheep have sold this morning after just 6months they were putting this down as a buy! RHPS is a waste of time IMHO and i'm glad he did sell to give me my entry price today. Launch of MIDAS is expected very soon so could be a great time to buy. DYOR as always. GLA

I won't fill up the bb anymore, it takes 2mins to register and is free. Worth reading the rest... GL

One of the key criteria for the merger / takeover of Curidium in early 2009, apart from its unaudited cash pile and other financial assets of approximately £2 million, was to strengthen the group's ability to deliver a range of commercially valuable and clinically effective diagnostic products in personalised medicine based off the proprietary analysis tool developed by Curidium – HomomatrixTM. Alastair believes that the market may not have understood the potential value of this analysis tool and says that, because it offers a different approach by looking at RNA (Ribonucleic acid) or proteins rather than just DNA, it is potentially a lot more powerful and future personalised medicine diagnostic tests could be based off this science. Curidium has a valuable strategic partnership with Takeda Research Investment Inc, which was announced in December 2007. There were a number of milestone payments attached to this partnership agreement which would be due to Curidium subject to certain milestones achieved within a 22 month time frame. This timeframe has now expired and Alastair was naturally very reluctant to divulge any information due to strict confidentiality agreements with Takeda but he did say that ‘we are very pleased with the outcome of the work and we would hope that there is potential now to expand the type of work Curidium have done with Takeda and to generate some significant and profitable opportunities with other pharmaceutical companies. Curidium has a unique offering, which should be strongly validated by a positive outcome of the work with Takeda, and we are looking forward to monetising that offering’. As an accompanying source of research to this article, I recommend that any prospective investor trying to get to grips with “Personalised Medicine” should read the PriceWaterhouseCoopers (PWC) article published in December 2009, “The New Science of Personalized medicine: Translating the Promise into Practice”(http://www.pwc.com/personalizedmedicine). I found this research note especially useful. Reducing risk and cost for drug developers - Optim The Optim technology is currently the flagship product of Avacta Group and is a unique offering; allowing biopharmaceutical companies the ability to gain vital information about compounds using tiny samples far quicker and more cheaply than existing methods. This information is designed to assist drug developers in making the right decisions about drugs and formulations to take forward in development, reducing future risk of failure and the overall cost of bringing drugs to market.